EVMN Evommune, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 2044725 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-84.4%
TTM EPS YoY131.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-331.4%
ROA-62.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets9.7%
Debt / equity0.00x
Current ratio8.52x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.80x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $13.00M | $7.00M |
| R&D expense | $74.04M | $64.24M |
| SG&A expense | $20.03M | $12.77M |
| Operating income | -$81.07M | -$70.01M |
| Pretax income | -$68.87M | -$68.31M |
| Income tax | $0 | $0 |
| Net income | -$68.87M | -$66.81M |
| EBITDA | -$80.47M | -$69.51M |
| EPS (basic) | -11.22 | -45.29 |
| EPS (diluted) | -11.22 | -45.29 |
| Weighted avg. shares (diluted) | 6.14M | 1.51M |
| Balance sheet | ||
| Cash & equivalents | $44.06M | $16.46M |
| Short-term investments | $105.14M | $55.78M |
| Current assets | $153.48M | $73.99M |
| PP&E, net | $994,000 | $1.33M |
| Total assets | $224.95M | $76.06M |
| Current liabilities | $17.91M | $27.98M |
| Total liabilities | $19.38M | $28.52M |
| Shareholders' equity | $205.57M | -$144.24M |
| Shares outstanding | 31.52M | 1.55M |
| Cash flow statement | ||
| Operating cash flow | -$76.44M | -$58.20M |
| Capital expenditure | $235,000 | $88,000 |
| Free cash flow | -$76.68M | -$58.28M |
| Investing cash flow | -$115.31M | -$3.99M |
| Financing cash flow | $220.76M | $49.42M |
| Depreciation & amortization | $600,000 | $500,000 |
| Stock-based compensation | $5.86M | $1.72M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.